During the corresponding time, Castle Biosciences Inc recorded a revenue increase by 20.14 % year on year, sequentially revenue grew by 23.74 %. While revenue at the Castle Biosciences Inc 's corporate clients
Castle Biosciences Inc's Comment on Sales, Marketing and Customers
The company holds a global patent portfolio encompassing proprietary tests, methods, and systems for diagnosing and treating medical conditions such as cutaneous melanoma, pigmented skin lesions, squamous cell carcinoma, atopic dermatitis, psoriasis, uveal melanoma, Barrett's esophagus, and cancer metastasis. It maintains its proprietary position through patents, trademarks, trade secrets, know-how, technological innovation, and potential in-licensing opportunities. Washington University in St. Louis (WUSTL) is identified as a customer or market participant in related filings.
: The evolving landscape of melanoma diagnosis and management continues to demand innovative tools for precise risk stratification, particularly for early-stage patients. Recent presentations at the AACR Annual Meeting 2025 underscore the promising role of DecisionDx-Melanoma, a multi-gene expression profile test, in identifying patients at heightened risk for distant metastasis. This article synthesizes the latest data and discusses its implications for clinical practice, highlighting how such advancements can potentially refine therapeutic strategies and improve patient outcomes in both cutaneous and uveal melanoma.Melanoma remains one of the deadliest forms of skin cancer, with its propensity for early m...
Castle Biosciences is poised to present compelling new data supporting the clinical utility of the DecisionDx-Melanoma test at the upcoming 11th World Congress of Melanoma and the 21st European Association of Dermato-Oncology (EADO) Congress. This innovative genomic test promises to refine risk assessment and management pathways for melanoma patients, offering vital insights that can lead to more personalized treatment approaches. Melanoma, characterized by its aggressive behavior and potential for metastasis, poses significant challenges in patient management and treatment decision-making. As our understanding of melanoma s genetic landscape expands, it becomes increasingly clear that personalized appro...
Castle Biosciences Inc’s Comment on Sales, Marketing and Customers
The company holds a global patent portfolio encompassing proprietary tests, methods, and systems for diagnosing and treating medical conditions such as cutaneous melanoma, pigmented skin lesions, squamous cell carcinoma, atopic dermatitis, psoriasis, uveal melanoma, Barrett's esophagus, and cancer metastasis. It maintains its proprietary position through patents, trademarks, trade secrets, know-how, technological innovation, and potential in-licensing opportunities. Washington University in St. Louis (WUSTL) is identified as a customer or market participant in related filings.
Sources:
Castle Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Castle Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Castle Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
39.7 %